{
    "2021-05-31": [
        [
            {
                "time": "",
                "original_text": "贝达药业通过港交所聆讯，恩沙替尼有望成公司首个出海品种！",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港交所",
                        "聆讯",
                        "恩沙替尼",
                        "出海品种"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：刊发H股发行聆讯后资料集",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "H股",
                        "聆讯后资料集"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药周报：骨修复材料市场增速近20% 人工材料为骨移植的新选择",
                "features": {
                    "keywords": [
                        "骨修复材料",
                        "市场增速",
                        "人工材料",
                        "骨移植"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "A股异动|贝达药业(300558.SZ)涨4.44%通过港交所上市聆讯",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "A股",
                        "异动",
                        "港交所",
                        "聆讯"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "快讯 | 贝达药业通过港交所上市聆讯，目前已两款靶向创新药上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港交所",
                        "聆讯",
                        "靶向创新药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业通过港交所聆讯，国内肺癌靶向药市场排名第一",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港交所",
                        "聆讯",
                        "肺癌靶向药",
                        "市场排名"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "港股IPO|贝达药业通过聆讯，收入主要来源抗癌药的销售",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港股IPO",
                        "聆讯",
                        "抗癌药",
                        "销售"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：恩沙替尼一线治疗ALK突变NSCLC的国际多中心三期临床研究目前正常推进中",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩沙替尼",
                        "ALK突变",
                        "NSCLC",
                        "临床研究"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[新股IPO]贝达药业已通过港交所上市聆讯",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "新股IPO",
                        "港交所",
                        "聆讯"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "港交所文件：制药企业贝达药业股份有限公司通过港交所上市聆讯",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港交所",
                        "聆讯",
                        "制药企业"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[IPO追踪]贝达药业通过上市聆讯传集资达78亿元",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "IPO追踪",
                        "上市聆讯",
                        "集资"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}